We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Synairgen (SNG) ORD GBP 0.01

Sell:6.02p Buy:7.48p 0 Change: No change
Market closed |  Prices as at close on 19 April 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:6.02p
Buy:7.48p
Change: No change
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 19 April 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Sell:6.02p
Buy:7.48p
Change: No change
Market closed |  Prices as at close on 19 April 2024 Prices delayed by at least 15 minutes | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Synairgen plc is a United Kingdom-based holding company for Synairgen Research Limited, which is a respiratory drug discovery and development company; Synairgen Inc. and Synairgen Research (Ireland) Limited. The Company is developing SNG001, an investigative formulation of inhaled interferon beta (IFN-B), for the treatment and prevention of various viral lung infections in high-risk patient groups. The Company has developed and is testing an inhaled formulation of IFN-B designed to directly target the lungs, the primary site of many viral lung infections, including COVID-19.

Contact details

Address:
Southampton General Hosp, Tremona Road
SOUTHAMPTON
SO16 6YD
United Kingdom
Telephone:
+44 (023) 80512800
Website:
https://www.synairgen.com/

Important dates

Future events
There are no future events available.
Past events
Interim results 21 September 2023 21/09/23
AGM 29 June 2023 29/06/23
Final results 27 April 2023 27/04/23

General stock information

EPIC:
SNG
ISIN:
GB00B0381Z20
Market cap:
£13.29 million
Shares in issue:
201.37 million
Sector:
Pharmaceuticals & Biotechnology
Exchange:
London Stock Exchange
Currency:
Sterling pence
Indices:
n/a

Key personnel

  • Richard Marsden
    Chief Executive Officer, Executive Director
  • Joseph Colliver
    Chief Financial Officer, Executive Director
  • Helen Gearing
    Senior Vice President - Finance
  • Richard Francis
    Senior Vice President, Head of CMC and Quality
  • Phillip Monk
    Chief Scientific Officer, Executive Director
  • Richard Hennings
    Chief Commercial Officer
  • Marcin Mankowski
    Chief Medical Officer
  • Gareth Walters
    Chief Regulatory Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by NBTrader.
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.